Errazquin Ricardo, Carrasco Estela, Del Marro Sonia, Suñol Anna, Peral Jorge, Ortiz Jessica, Rubio Juan Carlos, Segrelles Carmen, Dueñas Marta, Garrido-Aranda Alicia, Alvarez Martina, Belendez Cristina, Balmaña Judith, Garcia-Escudero Ramon
Research Institute Hospital 12 de Octubre (Imas12), University Hospital 12 de Octubre, Av Cordoba s/n, 28041 Madrid, Spain.
Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas), Avenida Complutense 40, 28040 Madrid, Spain.
Cancers (Basel). 2023 Mar 21;15(6):1871. doi: 10.3390/cancers15061871.
Fanconi anemia (FA) patients display an exacerbated risk of oral squamous cell carcinoma (OSCC) and oral potentially malignant lesions (OPMLs) at early ages. As patients have defects in their DNA repair mechanisms, standard-of-care treatments for OSCC such as radiotherapy and chemotherapy, give rise to severe toxicities. New methods for early diagnosis are urgently needed to allow for treatment in early disease stages and achieve better clinical outcomes. We conducted a prospective, longitudinal study wherein liquid biopsies from sixteen patients with no clinical diagnoses of OPML and/or OSCC were analyzed for the presence of mutations in cancer genes. The DNA from saliva and plasma were sequentially collected and deep-sequenced, and the clinical evaluation followed over a median time of approximately 2 years. In 9/16 FA patients, we detected mutations in cancer genes (mainly ) with minor allele frequencies (MAF) of down to 0.07%. Importantly, all patients that had mutations and clinical follow-up data after mutation detection ( = 6) developed oral precursor lesions or OSCC. The lead-time between mutation detection and tumor diagnosis ranged from 23 to 630 days. Strikingly, FA patients without mutations displayed a significantly lower risk of developing precursor lesions or OSCCs. Therefore, our diagnostic approach could help to stratify FA patients into risk groups, which would allow for closer surveillance for OSCCs or precursor lesions.
范可尼贫血(FA)患者在早年患口腔鳞状细胞癌(OSCC)和口腔潜在恶性病变(OPML)的风险加剧。由于患者的DNA修复机制存在缺陷,OSCC的标准治疗方法如放疗和化疗会产生严重毒性。迫切需要新的早期诊断方法,以便在疾病早期进行治疗并取得更好的临床结果。我们进行了一项前瞻性纵向研究,对16例无OPML和/或OSCC临床诊断的患者进行液体活检,分析癌症基因中的突变情况。依次收集唾液和血浆中的DNA并进行深度测序,并在约2年的中位时间内进行临床评估。在16例FA患者中的9例中,我们检测到癌症基因中的突变(主要是 ),次要等位基因频率(MAF)低至0.07%。重要的是,所有检测到突变并在突变检测后有临床随访数据的患者( = 6)均出现口腔前驱病变或OSCC。突变检测与肿瘤诊断之间的提前期为23至630天。引人注目的是,没有突变的FA患者发生前驱病变或OSCC的风险显著较低。因此,我们的诊断方法有助于将FA患者分层为风险组,从而可以对OSCC或前驱病变进行更密切的监测。